Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:3 Issue:7 Number:89 ISSN#:2563-5476
Author Verified
RCT
ACE Report #5476
Ace Report Cover Pediatric Orthopaedics

Oral alendronate cannot yet be recommended for children with OI


How to Cite

OrthoEvidence. Oral alendronate cannot yet be recommended for children with OI. ACE Report. 2014;3(7):89. Available from: https://myorthoevidene.com/AceReport/Report/5476

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study

J Clin Endocrinol Metab. 2011 Feb;96(2):355-64

Contributing Authors: LM Ward F Rauch MP Whyte J D'Astous PE Gates D Grogan EL Lester RE McCall TA Pressly JO Sanders PA Smith RD Steiner E Sullivan G Tyerman DL Smith-Wright N Verbruggen N Heyden A Lombardi FH Glorieux

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

139 children and adolescents with moderate to severe osteogenesis imperfecta (OI) were randomized to evaluate the safety and efficacy of oral alendronate (ALN). The trial primarily focused on the assessment of lumbar spine bone mineral density (LS BMD) alongside several secondary critera/data: clinical, radiological, biochemical, and multiple bone-related measurements and fracture details. Results...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.